

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12Q 1/68 // A61P 9/10</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/63430</b> <b>(43) International Publication Date:</b> 26 October 2000 (26.10.00)
<b>(21) International Application Number:</b> PCT/FI00/00260 <b>(22) International Filing Date:</b> 29 March 2000 (29.03.00) <b>(30) Priority Data:</b> 09/291,994 15 April 1999 (15.04.99) US <b>(71) Applicant (for all designated States except US):</b> HORMOS MEDICAL OY LTD. [FI/FI]; Tykistökatu 6 A, FIN-20520 Turku (FI). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> KOULU, Markku [FI/FI]; Kotikatu 4 B 8, FIN-20700 Turku (FI). KARVONEN, Matti [FI/FI]; Kaskenkatu 11 C 54, FIN-20700 Turku (FI). PESONEN, Ullamari [FI/FI]; Luodikkokuja 6, FIN-20900 Turku (FI). UUSITUPA, Matti [FI/FI]; Vällilähdentie 10, FIN-70260 Kuopio (FI). <b>(74) Agent:</b> TURUN PATENTTITOIMISTO OY; P.O. Box 99, FIN-20521 Turku (FI).		<b>(81) Designated States:</b> AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> DIAGNOSIS OF A PERSON'S RISK FOR DEVELOPING ATHEROSCLEROSIS OR DIABETIC RETINOPATHY		
<b>(57) Abstract</b>  The invention relates to methods for diagnosing a person's susceptibility for having an increased risk for the development of atherosclerosis and a diabetic person's susceptibility for having an increased risk for the development of diabetic retinopathy. The invention relates further to methods for treating persons diagnosed for having increased risk for the development of said diseases. The invention also concerns methods to investigate or screen pharmaceuticals or genetic aims useful in the treatment of said diseases, by using an animal model including a transgenic animal. The methods of the invention are based on Leucine 7 to proline 7 polymorphism in the prepro neuropeptide Y gene.		